ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

takeda pharma a/s - darvadstrocel - tiesiosios Žarnos fistula - imunosupresantai - alofisel fluorouracilu ir folino sudėtingų išangės fistulas suaugusiųjų pacientų su non-active/mažai aktyvus luminal krono liga, kai fistulas parodė, nepakankamas atsakas į bent vieną paprastųjų arba biologinės terapijos. alofisel turėtų būti naudojamas po kondicionavimas fistula.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hidrochloridas - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresantai - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

লিত্ভা - লিথুয়েনীয় - Ecolab

ecolab deutschland gmbh -

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantais, pasirinktinio imunosupresantais - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

sandoz gmbh - natalizumabas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

vioser s.a. parenteral solutions industry - metronidazolas - infuzinis tirpalas - 500 mg/100 ml - metronidazole

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

as kalceks - atrakurio besilatas - injekcinis ar infuzinis tirpalas - 10 mg/ml - atracurium

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

octapharma (ip) sprl - Žmogaus normalusis imunoglobulinas - injekcinis tirpalas - 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - narkolepsija - kiti nervų sistemos vaistai - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

baxter holding b.v. - propofolis - injekcinė ar infuzinė emulsija - 10 mg/ml; 20 mg/ml - propofol